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Introduction: Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quanti-
ﬁcation have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-
speciﬁc atrophy quantiﬁcation method, MSmetrix, has become commercially available. Here we perform a
validation of MSmetrix against established methods in simulated and in vivo MRI data.
Methods: Whole-brain and gray matter (GM) volume were measured with the cross-sectional pipeline of
MSmetrix and compared to the outcomes of FreeSurfer (cross-sectional pipeline), SIENAX and SPM. For this
comparison we investigated 20 simulated brain images, as well as in vivo data from 100 MS patients and 20
matched healthy controls. In ﬁfty of the MS patients a second time point was available. In this subgroup, we
additionally analyzed the whole-brain and GM volume change using the longitudinal pipeline of MSmetrix and
compared the results with those of FreeSurfer (longitudinal pipeline) and SIENA.
Results: In the simulated data, SIENAX displayed the smallest average deviation compared with the reference
whole-brain volume (+19.56 ± 10.34 mL), followed by MSmetrix (−38.15 ± 17.77 mL), SPM
(−42.99 ± 17.12 mL) and FreeSurfer (−78.51 ± 12.68 mL). A similar pattern was seen in vivo. Among the
cross-sectional methods, Deming regression analyses revealed proportional errors particularly in MSmetrix and
SPM. The mean diﬀerence percentage brain volume change (PBVC) was lowest between longitudinal MSmetrix
and SIENA (+0.16 ± 0.91%). A strong proportional error was present between longitudinal percentage gray
matter volume change (PGVC) measures of MSmetrix and FreeSurfer (slope = 2.48). All longitudinal methods
were sensitive to the MRI hardware upgrade that occurred during the time of the study.
Conclusion: MSmetrix, FreeSurfer, FSL and SPM show diﬀerences in atrophy measurements, even at the whole-
brain level, that are large compared to typical atrophy rates observed in MS. Especially striking are the pro-
portional errors between methods. Cross-sectional MSmetrix behaved similarly to SPM, both in terms of mean
volume diﬀerence as well as proportional error. Longitudinal MSmetrix behaved most similar to SIENA. Our
results indicate that brain volume measurement and normalization from T1-weighted images remains an un-
solved problem that requires much more attention.
1. Introduction
In the past decade, brain atrophy in multiple sclerosis (MS) has been
recognized as a crucial component of the disease (Bermel and Bakshi,
2006). Especially gray matter (GM) atrophy has attracted a lot of at-
tention because (i) it could be present in early phases of the disease
(Calabrese et al., 2015), (ii) it shows a diﬀerent course across clinical
subtypes (Fisher et al., 2008), and (iii) it shows stronger associations
with clinical (especially cognitive) dysfunction than the well-known
focal white matter pathology (Bermel and Bakshi, 2006). Although the
exact mechanism underlying GM tissue loss in MS remains to be elu-
cidated (Chard and Miller, 2016), atrophy measures are now widely
accepted as a surrogate marker for neurodegeneration and disease
progression in research. The importance of brain atrophy in MS is
further illustrated by the increasing number of recent clinical trials that
used brain atrophy measures as outcome measures (Cohen et al., 2010,
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MARK
2015; Comi et al., 2012; Kappos et al., 2007; Mikol et al., 2008;
O'Connor et al., 2011; Olsson et al., 2014).
Although atrophy in MS is substantially faster than in normal ageing
(Fisher et al., 2008), accurate and sensitive quantiﬁcation of atrophy in
MS remains challenging (Vrenken et al., 2013). Firstly, the presence of
MS pathology other than atrophy (e.g., gray and white matter MS le-
sions and diﬀuse abnormalities) severely complicates reliable mea-
surement of atrophy in MS patients using “standard” image analysis
techniques. Secondly, reliable atrophy measurements require 3D ima-
ging, while most institutions and clinical trials still tend to use tradi-
tional 2D sequences. Finally, and most importantly, due to the lack of
standardized benchmark datasets, only a few studies have system-
atically evaluated the accuracy and reproducibility of the atrophy
measurement techniques that are widely available and generally used
in research, trial and clinical settings (Derakhshan et al., 2010; Eggert
et al., 2012; Klauschen et al., 2009).
Recently, the MSmetrix software package (Icometrix, Flanders,
Belgium) has received CE labeling and FDA approval for the automatic
quantiﬁcation of cerebral (and WM lesion) volumes from FLAIR and T1-
weighted images in patients with MS (Jain et al., 2015; Lysandropoulos
et al., 2016; Smeets et al., 2016). MSmetrix accepts any of these clinical
sequences (FLAIR with a maximum slice thickness of 3 mm) and gen-
erates an online report with the measured white matter lesion, whole-
brain and gray matter volumes. MSmetrix's approval gives patients and
physicians access to a new generation of disease monitoring tools,
which are speciﬁcally developed to measure atrophy at an individual
level in a clinical setting, as well as being tailored to MS patients.
However, a thorough evaluation of MSmetrix has not been performed
yet. Therefore, the aim of the current study was to compare MSmetrix
with three established atrophy measurement techniques, i.e. FreeSurfer,
SIENA(x) and SPM. We ﬁrstly compared the cross-sectional MSmetrix
results with known reference values and the results of the established
methods in simulated data. Secondly, we compared the cross-sectional
and longitudinal MSmetrix results with the established methods in
‘real’, in vivo MR images of MS patients and healthy controls.
2. Materials and methods
2.1. Data
To evaluate the agreement of the diﬀerent atrophy measurement
methods, we used i) 20 simulated single time-point T1-weighted images
of healthy controls provided by the Simulated Brain Database (http://
brainweb.bic.mni.mcgill.ca/brainweb/) and ii) in vivo MR images of
100 MS patients and 20 healthy controls, of whom 50 MS patients and 8
healthy controls also had longitudinal follow-up data.
2.1.1. Simulated MRI data
The BrainWeb data set consists of twenty simulated MR images
based on the anatomical models of healthy controls (Aubert-Broche
et al., 2006a, 2006b). For this study, we used the 3D T1-weighted
spoiled FLASH sequence (1.5 Tesla, TR = 22 ms, TE = 9.2 ms,
FA = 30°, 1 mm isotropic voxels) simulated with 3% noise and 0%
intensity-inhomogeneity. The anatomical subject of each model consists
of 12 volumes that each describe the voxelwise fuzzy membership
(comparable with partial volume) for the corresponding tissue class
(background, CSF, GM, WM, fat, muscle, muscle/skin, skull, vessels,
‘tissue around fat’, dura mater and bone marrow). For each subject, we
estimated the reference total brain volume from these anatomical
models adding up the voxelwise GM and WM memberships across the
entire image. As the FLAIR image contrast is not available for the
BrainWeb images, all atrophy measurements on simulated data were
performed on the T1-weighted images only.
2.1.2. In vivo MRI data
The in vivo data set was selected from two ongoing study cohorts
acquired at the MS Center Amsterdam, VU University medical center
Amsterdam, consisting of patients with clinically-deﬁnite MS and
matched healthy controls (Schoonheim et al., 2012; Steenwijk et al.,
2014). The institutional ethics review board approved the study pro-
tocol and subjects gave written informed consent prior to participation.
We randomly selected a subset of 100 MS patients of whom 50 had
longitudinal follow-up. Disease severity was measured on the day of
scanning using the expanded disability status scale (EDSS) (Kurtzke,
1983). The baseline cohort consisted of 100 MS patients (65% female)
with an average (± standard deviation) age of 43.49 ± 10.19 years,
disease duration of 9.95 ± 6.93 years, and median EDSS score of 3
(range: 0–8). The matched control group consisted of 20 healthy vo-
lunteers, with an average age of 43.34 (± 10.21) years of which 15
(75%) were female. The subset of ﬁfty MS patients (64% female) who
had longitudinal follow-up were on average 43.81 ± 10.53 years old
at baseline, had a baseline disease duration of 9.98 ± 7.41 years, a
median baseline EDSS of 3 (range: 0–6.5), and a mean follow-up time of
4.92 ± 0.95 years (range: [3.03, 6.33] years). The 7 healthy controls
(43% female) with follow-up were at baseline on average
38.72 ± 7.45 years old, and had a mean follow-up time of
6.20 ± 0.62 years (range: [5.02, 6.33] years).
MRI was performed using a clinical 3.0 T whole body scanner (GE,
Milwaukee, WI, USA). The system underwent a hardware upgrade be-
tween the baseline (Signa HDxt) and the follow-up acquisition
(Discovery MR750). At both time points, the same eight-channel head
coil was used. The imaging protocol was identical at baseline and
follow-up, containing among others a 3D T1-weighted fast spoiled
gradient echo (FSPGR) sequence (TR = 7.8 ms, TE = 3 ms, FA = 12°,
240 × 240 mm2 ﬁeld of view (FOV), 176 sagittal slices of 1 mm,
0.94 × 0.94 mm2 in-plane resolution) for anatomical information and a
fat-saturated 3D ﬂuid attenuated inversion recovery (FLAIR) sequence
(TR = 8000 ms, TE = 125 ms, TI = 2350 ms, 250 × 250 mm2 FOV,
132 sagittal slices of 1.2 mm, 0.98 × 0.98 mm2 in-plane resolution) for
MS lesion detection. All baseline measurements were taken before the
upgrade and all follow-up measurements were taken after the upgrade.
2.2. Image analysis
In this study, we assessed the agreement of cross-sectional atrophy
measurement methods (MSmetrix, FreeSurfer, SIENAX, and SPM) as
well as the agreement of longitudinal atrophy measurement methods
(longitudinal MSmetrix, longitudinal FreeSurfer, and SIENA). Prior to
measuring atrophy, all image data was anonymized, corrected for
geometric distortions due to gradient non-linearities, and converted to
nifti ﬁle format. Icometrix (Leuven, Flanders, Belgium) performed the
MSmetrix analyses while being blinded to subject characteristics, ex-
cept that they were informed whether the subject was an MS patient or
healthy control: lesion segmentation was actively removed from the
MSmetrix processing pipeline when the data of a healthy control was
analyzed. The other analyses were performed at VU University medical
center.
2.2.1. MSmetrix: cross-sectional and longitudinal analysis
MSmetrix has a separate cross-sectional and longitudinal pipeline of
which the details are published elsewhere (Jain et al., 2015;
Lysandropoulos et al., 2016; Smeets et al., 2016). In short, the cross-
sectional pipeline combines lesion segmentation, lesion ﬁlling and
tissue segmentation in an iterative algorithm that converges to seg-
mentations that allow for measurement of lesion volume, whole-brain
volume (BV), and gray matter volume (GMV). Since lesion ﬁlling is
embedded in the segmentation pipeline, it is not necessary to perform
lesion ﬁlling prior to applying MSmetrix. MSmetrix normalizes for head
size by computing a factor from a matrix that linearly transforms the
subjects' T1-weighted image to MNI152 standard space. The long-
itudinal pipeline analyzes two time points: it takes the cross-sectional
segmentations of both time points and uses a non-linear registration
M.D. Steenwijk et al. NeuroImage: Clinical 15 (2017) 843–853
844
approach to derive the percentage change of whole-brain (PBVC) and
gray matter (PGVC) volume. Icometrix did not have access to the seg-
mentation results of the established atrophy measurement methods,
which were created at the VU University medical center.
2.2.2. Established methods: preprocessing
In contrast to MSmetrix, the established atrophy measurement
methods did not include lesion ﬁlling by default. Therefore, the images
were preprocessed to reduce the impact of hypo-intense MS lesions on
the segmentations. This involved segmentation of the WM lesions from
the 3D FLAIR images using k-Nearest Neighbor classiﬁcation with
Tissue Type Priors (kNN-TTP) (Steenwijk et al., 2013) and lesion ﬁlling
on the 3D T1-weighted images using Lesion Automated Processing
(LEAP) (Chard et al., 2010). A detailed explanation of the pipeline can
be found elsewhere (Steenwijk et al., 2014).
2.2.3. Established cross-sectional methods: FreeSurfer, SIENAX and SPM
- FreeSurfer 5.3 (http://surfer.nmr.mgh.harvard.edu) was used to
derive FreeSurfer estimated total intracranial volume (eTIV), brain
volume (BV), gray matter volume (GMV) and white matter volume
(WMV). Although FreeSurfer is speciﬁcally optimized for cortical
thickness measurements, the pipeline has also been used for quan-
tiﬁcation of whole-brain atrophy. Normalization for diﬀerences in
head size was done by computing the ratio of tissue volumes com-
pared to eTIV, resulting in brain parenchymal fraction (BPF), gray
matter fraction (GMF), and white matter fraction (WMF).
- SIENAX (part of FSL 5.0.4, http://www.fmrib.ox.ac.uk/fsl), a soft-
ware package commonly used for cross-sectional atrophy measure-
ments in MS, was also used to obtain BV, GMV and WMV. To ensure
optimal brain extraction, the brain extraction tool was employed
using optimized parameter settings as recommended previously,
yielding bias ﬁeld correction and a liberal -f (i.e., fractional in-
tensity) threshold of 0.2 (Popescu et al., 2012). We did not optimize
the brain extraction settings for each subject individually, as it is
known that diﬀerences in CSF layer thickness may aﬀect the SIENAX
GM/WM segmentation results (Popescu et al., 2011). SIENAX per-
forms normalization for head size by obtaining a scaling factor that
normalizes the skull of each subject to the skull in the MNI standard
space to obtain NBV, NGMV and NWMV.
- SPM12 (http://www.ﬁl.ion.ucl.ac.uk/spm/software/spm12), an-
other software package commonly used for atrophy measurements
in MS, was also used to compute BV, GMV, WMV and total in-
tracranial volume (TIV = GMV+WMV+ CSF volume).
Normalization for diﬀerences in head size was done by computing
the fraction of tissue with respect to TIV, resulting in BPF, GMF, and
WMF. The default processing parameters were used.
2.2.4. Established longitudinal methods: FreeSurfer and SIENA
- The longitudinal FreeSurfer 5.3 pipeline was used to derive per-
centage brain volume change (PBVC) and percentage gray matter
volume change (PGVC). The longitudinal FreeSurfer pipeline aims
to reduce measurement errors that can be induced by diﬀerent in-
itialization of the algorithm at diﬀerent time points.
- SIENA (part of FSL), another software package commonly used for
longitudinal whole-brain atrophy measurement in MS and even
being used as secondary outcome parameter in clinical trials, was
also used to compute PBVC (Smith et al., 2002). Optimal brain ex-
traction was ensured by using optimized parameter settings
(Popescu et al., 2012).
2.3. Impact of the hardware upgrade
To investigate the impact of the hardware upgrade on the cross-
sectional and longitudinal atrophy measurement methods, we also
investigated an independent validation cohort of 13 healthy males who
were scanned just before and directly after the upgrade, which took
about six months to complete. The mean age of this sample was
33.96 ± 8.63 years at baseline, and the mean time to follow-up time
was 6.22 ± 0.70 months. The impact of the upgrade was measured for
all abovementioned methods.
We evaluated the impact of the scanner upgrade on cross-sectional
methods by computing the percentage volume change from baseline
(before the upgrade) to follow-up (after the upgrade) in the validation
cohort. A paired t-test was used to investigate diﬀerences between the
time points. The impact of the scanner upgrade on longitudinal
methods was evaluated by computing the longitudinal percentage vo-
lume change between the two time points. Since the validation cohort
consisted of relatively young healthy controls, and the follow-up time
was approximately 6 months, close to zero brain volume changes
should be expected (Fjell et al., 2009; Raz et al., 2005; Resnick et al.,
2003).
2.4. Statistical analysis
Statistical analyses were performed in IBM Corp. Released, 2011
and Matlab R2011a (Mathworks, Natick, MA).
The between-method agreement of normalized cross-sectional
whole-brain and gray matter atrophy measures was assessed by com-
puting Spearman-rank correlations. The rationale for using Spearman-
rank correlations is that the units of the normalized atrophy measures
were diﬀerent (i.e., ratio versus ratio ∗ volume for BPF and NBV re-
spectively) and a non-linear relationship can be expected.
Mean volumetric was used to investigate the between method
agreement of the non-normalized (i.e., raw) atrophy measures. Deming
regression analysis was used to investigate the presence of ﬁxed and
proportional diﬀerences. In contrast to standard regression analysis,
Deming regression analysis computes the residue orthogonally to the
regression line itself. Thereby, the technique distributes the measure-
ment error over both the dependent and independent variable in the ﬁt.
This is necessary when two measurement techniques, each having a
measurement error, are compared.
To enhance the sensitivity to diﬀerences, we report uncorrected P-
values: in all analyses, P-values < 0.05 were considered as statistically
signiﬁcant.
3. Results
The average measurement results for each method and group are
presented in Supplementary Table 1 (cross-sectional methods) and
Supplementary Table 2 (longitudinal methods). A typical example of
the cross-sectional (lesion and gray matter) segmentation results in an
MS patient is displayed in Fig. 1.
3.1. Simulated MRI data: agreement of cross-sectional methods
The agreement of the raw (i.e., non-normalized) cross-sectional
atrophy measurement methods with the estimated reference volumes
and each other is presented in Table 1 and Fig. 2. SIENAX displayed on
average the smallest deviation from the whole-brain reference volume
(mean diﬀerence: +19.56 ± 10.34 mL), while MSmetrix and SPM
showed larger average deviations (mean diﬀerence:
−38.46 ± 15.77 mL and −42.99 ± 17.12 mL, respectively). Free-
Surfer showed the largest deviation from the whole-brain reference
volume (mean diﬀerence: −78.51 ± 12.68 mL). The regression ana-
lyses revealed trends towards proportional errors in the brain volumes
measured by MSmetrix and SPM: both methods tend to increasingly
underestimate brain volume with increasing reference brain volumes
(see Fig. 2A and D). The FreeSurfer and SIENAX whole-brain results did
not show such a trend.
Similar characteristics were observed in the gray matter: SIENAX
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displayed the smallest average deviation from the reference gray matter
volumes (mean diﬀerence: +12.08 ± 13.15 mL), while MSmetrix and
SPM showed larger deviations (mean diﬀerence: −31.66 ± 24.40 mL
and−29.89 ± 27.96 mL, respectively). Again, FreeSurfer showed the
largest average deviation, with a mean diﬀerence of
−48.66 ± 22.85 mL. All methods showed signiﬁcant proportional
errors with respect to the reference gray matter volume (i.e., the slope
of the regression line between reference and method-wise gray matter
volume diﬀered signiﬁcantly from 1), reporting lower gray matter vo-
lumes for subjects with more true gray matter (see Table 1). Propor-
tional errors were smallest in SIENAX and FreeSurfer (slope = 0.86 and
slope = 0.72, respectively), while SPM and MSmetrix showed the lar-
gest proportional errors (slope = 0.64 and slope = 0.68, respectively).
The agreement of the normalized cross-sectional atrophy measure-
ment results in the simulated MRI data is displayed in Table 2. At the
whole-brain level, a signiﬁcant correlation was only observed between
MSmetrix and SPM (ρ= 0.588, p= 0.006). For the gray matter, cor-
relations were observed between MSmetrix NGMV, SIENAX NGMV and
SPM GPF (all ρ > 0.60). FreeSurfer's normalized whole-brain and gray
matter atrophy measurements did not show a correlation with the other
methods at all.
3.2. In vivo MRI data: agreement of cross-sectional methods at baseline
Cross-sectional MSmetrix failed in two MS patients (both female) as
a result of a conversion error. These subjects were excluded from all
further analyses. One of them was originally included in the long-
itudinal cohort but was excluded due to this failure at baseline.
The in vivo agreement between the raw (i.e., non-normalized) cross-
sectional atrophy measurement methods at baseline was analyzed by
computing the mean diﬀerence (see Supplementary Table 3), per-
forming Deming regression analyses (see Supplementary Tables 4 and
5), and constructing scatter plots (see Fig. 3). When constructing the
scatter plots, SIENAX was selected as the reference because this method
showed the smallest deviation from the true reference volume in the
simulated MRI data.
In the pairwise comparison, diﬀerences at the whole-brain level
between methods were on average smaller than 10 mL. FreeSurfer de-
viated most from the other methods and showed the largest discrepancy
with SPM (mean diﬀerence: −35.57 ± 24.93 mL). Deming regression
analyses revealed a proportional error in brain volumes measured by
SPM compared to the other methods, overestimating the brain volume
for subjects with larger (true) brain volumes.
In the gray matter, MSmetrix and SPM showed the smallest mean
volumetric diﬀerence (12.15 ± 25.31 mL) closely followed by
FreeSurfer and SIENAX (−20.95 ± 10.72 mL). As can be seen in
Fig. 3, the MSmetrix-SPM and FreeSurfer-SIENAX pairs also showed
similar behaviour in terms of proportional errors. Of all gray matter
method pairs, the FreeSurfer-SIENAX combination was the only one
without a proportional error of one method with respect to the other
(see Supplementary Table 4). Most severe proportional errors were
observed in the gray matter volumes measured by SPM versus the other
methods, with a slope coeﬃcient of 1.26 (95% CI [1.19, 1.33]) for SPM
versus SIENAX.
The agreement of the normalized cross-sectional atrophy measure-
ments results in the in vivo MRI data at baseline is displayed in Table 3.
SPM was on average most consistent with the other methods. The
Fig. 1. An example of the cross-sectional segmentation results in a typical MS patient
drawn from the in vivo MRI dataset overlaid on the 3D T1-weighted image. The ﬁrst row
displays the raw 3D T1-weighted image. Red areas in the second and third row indicate
the lesions found by MSmetrix and kNN-TTP respectively. The lower four rows indicate
the voxelwise gray matter partial volume estimates (PVE; red: PVE = 0.01; yellow:
PVE = 1) of the diﬀerent cross-sectional tissue segmentation methods. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web version
of this article.)
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highest correlation at the whole-brain level was observed between
MSmetrix and SPM (ρ= 0.870, p < 0.001). FreeSurfer showed the
weakest average correlation with the other methods: the lowest corre-
lation was observed between MSmetrix and FreeSurfer (ρ= 0.664,
p < 0.001). Similar trends were seen for the gray matter, with SPM
showing the highest correlations with other methods and FreeSurfer the
lowest correlations. Also in the gray matter, MSmetrix and SPM showed
the highest correlation (ρ= 0.840, p < 0.001).
3.3. In vivo MRI data: agreement of longitudinal methods
For the longitudinal data, the mean diﬀerences between the
methods are displayed in Supplementary Table 6, and the results of the
Deming analyses are displayed in Supplementary Tables 7 and 8. A
visual impression is provided in Fig. 4. MSmetrix and SIENA showed the
smallest mean PBVC diﬀerence with respect to each other (mean PBVC
diﬀerence:−0.16 ± 0.91%), while the FreeSurfer-SIENA pair showed
the largest discrepancies (mean PBVC diﬀerence: −0.60 ± 1.26%).
All method-pairs displayed signiﬁcant proportional errors with respect
to each other, except for the FreeSurfer-SIENA pair (regression slope:
1.29, 95% CI [0.90, 1.67]).
Because the other longitudinal methods could not evaluate the gray
matter, MSmetrix PGVC was only compared with FreeSurfer PGVC. The
mean diﬀerence between these methods was relatively small (mean
PGVC diﬀerence: −0.20 ± 1.64%), but a strong proportional error
was observed between both methods (regression slope: 2.48, 95% CI
[1.14, 3.82]), indicating that the percentage change measured by
FreeSurfer is much larger than change found with MSmetrix.
3.4. In vivo MRI data: agreement of lesion segmentation
Because the diﬀerent approaches in lesion segmentation may have
aﬀected the in vivo atrophy measurements, we compared the lesion
volumes obtained by MSmetrix and kNN-TTP at baseline. This com-
parison revealed a high volumetric agreement between both methods
(ICC consistency = 0.969), but a Bland-Altman plot (see Fig. 5) and
Deming regression analysis revealed a proportional error between the
methods. MSmetrix reported signiﬁcantly higher lesion volumes than
kNN-TTP in patients with a high lesion load (raw data regression
slope = 1.06, 95% CI [1.01, 1.12]; log-transformed regression
slope = 1.11, 95% CI [1.06, 1.16]).
3.5. In vivo MRI data: eﬀect of hardware upgrade
The eﬀects of the hardware upgrade on the (cross-sectional and)
longitudinal measurements that were analyzed using the 13 healthy
controls in the validation cohort are discussed in the Supplementary
Materials. In short, the results of all longitudinal methods were aﬀected
by the upgrade. Some of the methods reported a mean percentage brain
volume change up to approximately 0.5%, while a volume change close
to zero was expected.
4. Discussion
In the current study, we compared atrophy measures obtained by
MSmetrix with those of established research techniques. Even at the
whole-brain level, our results demonstrated diﬀerences between
methods that were large compared to typical atrophy rates in MS and
were marked by strong proportional errors. Our results suggest that
cross-sectional MSmetrix behaves much like SPM, while the long-
itudinal MSmetrix results were reasonably consistent with those of
SIENA. In addition, our results indicate that brain volume measurement
and normalization from T1-weighted images remains an unsolved
problem that requires improvement both on the acquisition and the
analysis front.
4.1. Agreement of cross-sectional methods
In the simulated MRI data, our study conﬁrmed the ﬁndings of
several previous studies that performed a volumetric evaluation of
earlier versions of established cross-sectional atrophy measurement
techniques (Eggert et al., 2012; Klauschen et al., 2009). FreeSurfer and
SPM underestimated brain volume, while SIENAX overestimated the
volume but to a much smaller extent. In addition, our results indicate
strong proportional errors of the automatic methods compared to the
reference volume (i.e., they increasingly over- or underestimate vo-
lumes for larger true volumes). In the simulated MRI data, MSmetrix
behaved similarly to SPM, in terms of mean diﬀerence with the ground
truth and in exhibiting a similar proportional error. The similarity be-
tween both methods is probably best explained by the underlying
method, as both methods use an iterative approach to segment the
brain tissue, which is restricted by spatial, registration-based, regular-
ization. A diﬀerence between both methods is the approach to perform
lesion ﬁlling: while SPM was run from lesion ﬁlled images, MSmetrix
includes WM lesion segmentation and lesion ﬁlling in the main seg-
mentation loop. The latter may be advantageous because the segmen-
tation is iteratively reﬁned using this approach. However, a deep in-
vestigation of both methods at code level is required to unravel the
exact cause of the similar behaviour of both methods, which could be
part of future studies. Taking the results of the simulated raw volumes
Table 1
The raw whole-brain and gray matter volumes obtained by the cross-sectional methods compared with the reference
volume in the simulated MRI data.
Mean volume
difference in mL
a
Deming regression analysis
Slope
b
Standard error
A
l
l
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u
l
a
t
e
d
 
s
u
b
j
e
c
t
s
 
(
n
 
=
 
2
0
)
Whole–brain 
MSmetrix BV
FreeSurfer BV
SIENAX BV
SPM BV
–38.46 ± 15.77
–78.51 ± 12.68
+19.56 ± 10.34
–42.99 ± 17.12
0.91 [0.63 1.19]
1.01 [0.66 1.35]
1.01 [0.93 1.10]
0.87 [0.53 1.20]
11.05
9.23
7.50
11.71
Gray matter 
MSmetrix GMV
FreeSurfer GMV
SIENAX GMV
SPM GMV
–31.66 ± 24.40
–48.66 ± 22.85
+12.08 ± 13.15
–29.89 ± 27.96
0.68 [0.50 0.86] $
0.72 [0.61 0.83] $
0.86 [0.76 0.97] $
0.64 [0.42 0.86] $
12.69
12.65
7.83
14.93
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together, our data suggested that SIENAX was most consistent with the
reference volume. Therefore, SIENAX results were taken as a reference
in the in vivo analyses. However, it should be acknowledged that people
have debated the accuracy of BrainWeb to model partial volume eﬀects
in a realistic fashion (Bromiley, 2008). This lack in accuracy may ex-
plain discrepancies between methods in the simulated data to a certain
extent, and forces us to be cautious making statements on whether
SIENAX also performs best.
Large diﬀerences between methods appeared when comparing the
atrophy measures of the simulated MRI data between methods after nor-
malization for head size. While MSmetrix and SPM volume measurements
showed acceptable correlations, other method pairs showed severely dif-
ferent (and even inverted) associations. Given the fact that raw volumes did
not show such a bad correspondence between methods, the discrepancies
after normalization are most likely explained by diﬀerences in
normalization approaches themselves. We are not aware of other studies
that compared the normalization approaches between methods. Future
studies should further investigate these diﬀerences, as they are likely to
highly disturb atrophy measurements.
The in vivo results corroborated our ﬁndings in the simulated data.
Again, at the whole brain level, the average diﬀerence was smallest
between MSmetrix and SPM. However, the SPM volumes had a clear
proportional error with respect the other methods, measuring lower
brain volumes for smaller brains and larger brain volumes for larger
brains (see Fig. 2). FreeSurfer deviated most from the other methods,
underestimating the whole-brain volume on average by up to 3%, but it
should be acknowledged that FreeSurfer was originally not speciﬁcally
designed for measuring whole brain volumes. Instead, FreeSurfer was
speciﬁcally optimized for measuring cortical thickness, which we did
not evaluate in the current study.
Fig. 2. Scatter plots displaying the agreement of the raw whole-brain and gray matter volumes obtained by cross-sectional methods with the reference volumes in simulated MRI data.
The top row displays the measured whole brain volumes and corresponding ﬁts with respect to the reference whole brain volume. The bottom row displays the measured gray matter
volume ﬁts with respect to the reference gray matter volume.
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In the gray matter, we observed similar results, MSmetrix behaving
similar to SPM. However, in turn, SPM gray matter volume deviated
most from the SIENAX results which were closest to the reference in the
simulated data. In addition, the SPM gray matter volumes displayed the
strongest proportional errors with the other methods (regression slopes
down to 0.8). Taken together, this raises the question whether the vo-
lumes measured by MSmetrix (and SPM) are accurate in terms of
measuring the true brain volumes. The similar behaviour of MSmetrix
and SPM may be again be explained by the segmentation approach
underlying both methods, but it turns out that the precision of this
approach needs to be proven.
After normalization for head size, the correlations between methods
in the in vivo MRI data were much stronger than those observed in the
simulated MRI data. The highest correlations were observed between
MSmetrix and SPM. No clear diﬀerences in correlations were observed
between MS patients and healthy controls (data not shown). The
stronger correlations between methods in vivo may be explained by the
presence of more evident atrophy (i.e., inclusion of MS patients) and the
larger number of subjects included. Moreover, it could be that the skull
boundaries used to determine head size (or TIV) may appear slightly
artiﬁcial in the simulated data, each of the methods responding dif-
ferently. Future studies are necessary to further investigate this diﬀer-
ence.
4.2. Agreement of longitudinal methods
We additionally assessed the agreement of longitudinal atrophy
measurement methods. Given the absence of simulated longitudinal
data, we restricted the evaluation to the validation dataset (i.e., 13
right-handed male healthy controls scanned directly before and after
the hardware upgrade) and the in vivo data set. From the validation
dataset, it is clear that all longitudinal methods are sensitive to the
hardware upgrade. This upgrade is a clear limitation of our study, but
simultaneously reﬂects the importance of using identical hardware and
sequences for performing longitudinal atrophy measurements (Vrenken
et al., 2013). A recent study investigated the sensitivity of MSmetrix
and SIENA to changes in contrast by computing the PBVC between
1.5 T and 3.0 T data of 18 MS patients measured by both scanners at the
same day (Lysandropoulos et al., 2016). Here, the authors concluded
that MSmetrix is more robust to contrast changes than SIENA mea-
suring a ten-fold lower PBVC error when using MSmetrix. The better
robustness of longitudinal MSmetrix to the hardware upgrade in terms
of whole-brain volume change compared to SIENA was replicated in
our study, however we only detected a 2.5-fold improvement. When
considering the measurement of gray matter volume change, FreeSurfer
showed superior robustness compared to MSmetrix.
Aware of the eﬀect of the hardware upgrade, the results of the
longitudinal atrophy measurement in the current work have to be
interpreted with great care. One may suggest to post hoc correct the
longitudinal measurements with the values obtained in the validation
cohort, but we decided to not do so, since the validation cohort was
small and it is not known whether the hardware upgrade eﬀects have a
systematic and/or proportional nature. Given this limitation, the whole-
brain level changes measured by MSmetrix were on average closest to
those of SIENA, however, a substantial proportional error was present
between both methods. Changes in gray matter volume measured by
MSmetrix could only be compared to FreeSurfer: although the mean
diﬀerence between both methods was very small, again, a substantial
proportional error was present between the methods.
4.3. Atrophy measurement methods disagree and better evaluation is crucial
Our results indicate that brain volume measurement and normal-
ization of whole brain volumes on T1-weighted scans are still unsolved
problems that require much improvement on both the acquisition and
analysis fronts. Moreover, our data highlights the fact that proper va-
lidation of atrophy measurement methods deserves much more atten-
tion, both in MS as well as in neurodegenerative diseases in general.
Another recent study indicated that regional atrophy measurement
techniques tend to disagree when assessing correlations between re-
gional atrophy and clinical variables (Popescu et al., 2016). It is
alarming that, even when looking at the largest possible scale (i.e., the
whole-brain level), established atrophy measurement techniques hardly
agree on the actual brain volume that is present – even after lesion
ﬁlling and without normalization for head size. Some of the methods
even show proportional errors that depend on actual brain volume,
which may even become worse after normalizing for head size.
In the current work we show that group-averaged whole brain vo-
lumes may diﬀer up to 3% (around 35 mL) and gray matter volumes
may diﬀer up to 12% (around 83 mL) depending on the measurement
techniques used. Longitudinal atrophy measurements show more than a
two-fold diﬀerence in rate. These are unacceptable disagreements,
given the typical annual atrophy rates observed in MS (Fisher et al.,
2008) of whole brain (around 0.4%/y, which would be around 62 mL/y
at 1.5 L baseline volume) and of gray matter volume (around 0.4%/y,
which would be around 38 mL/y at a baseline GM volume of 0.95 L).
This raises questions as to the reliability of MRI studies that have
used atrophy measurements in MS, especially those studying regional or
local diﬀerences. It is clear that there is wide window for better algo-
rithms, yielding more accurate results and less subjects to be included
in clinical studies. Future work should address these issues by devel-
oping better algorithms and providing better proofs of their validity.
Improved benchmark dataset may help to achieve some of these goals.
In this regard, several characteristics of MSmetrix should also be
improved. First, the current study shows that cross-sectional atrophy
MSmetrix behaves much like SPM. Both methods show strong
Table 2
Spearman rank correlations between normalized cross-sectional atrophy measurement results in simulated MRI dataa.
A
l
l
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j
e
c
t
s
 
(
n
 
=
 
2
0
)
Whole–brain
MSmetrix NBV
FreeSurfer BPF
SIENAX NBV
SPM BPF
MSmetrix NBV
1
FreeSurfer BPF
–0.32
1
SIENAX NBV
0.26
–0.16
1
SPM BPF
0.59**
–0.15
0.13
1
Gray matter
MSmetrix NGMV
FreeSurfer GMF
SIENAX NGMV
SPM BPF
MSmetrix NGMV
1
FreeSurfer GMF
–0.28
1
SIENAX NGMV
0.62**
–0.11
1
SPM GMF
0.88***
–0.08
0.64**
1
a Spearman's ρ.
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proportional errors with respect to the true brain volumes, which may
be a serious drawback. Secondly, longitudinal MSmetrix suﬀered from
the hardware upgrade, although all methods did. This may be proble-
matic when intending to use the method in clinical practice, where data
from the same scanner is typically not available. Third, it is not clear to
what extent the estimates of MSmetrix' longitudinal gray matter
atrophy are accurate. Our results showed large discrepancies with
FreeSurfer's results, which is considered as the gold standard in this
ﬁeld. Lastly, the MSmetrix lesion segmentation routine should be im-
proved. Although the MSmetrix lesion segmentation algorithm per-
forms comparable to other methods available in the public domain, Jain
et al. acknowledged room for improvement given the fact that kNN-TTP
performed better in a direct comparison (Jain et al., 2015). Because of
the potential impact of these methodological uncertainties, it can be
rightly questioned whether the current version of MSmetrix is able to
fulﬁl its marketing promises (i.e., reliable individual atrophy
measurement, robust to scanner diﬀerences, use in clinical practice,
etc.). Moreover, little data exists on the value of atrophy measures in
clinical decision making (which is clearly a diﬀerent question and was
not within the scope of this study). All aspects together tend to suggest
that better algorithms and more thorough validations are necessary
before the use atrophy measurement methods can be considered in
clinical practice.
4.4. Limitations
Some limitations apply to this work. First, unblinding of MSmetrix
to the clinical characteristics of the subjects may be seen as a limitation.
We included healthy controls to provide a ‘connection’ between the in
vivo and simulated data. However, Icometrix applied a slightly diﬀerent
pipeline in the healthy controls (i.e., not including lesion segmentation
and ﬁlling) compared to the MS patients, which may have aﬀected our
Fig. 3. Scatter plots displaying the agreement of the raw whole-brain and gray matter volumes obtained by the cross-sectional methods with the SIENAX volumes in in vivo MRI data.
The top row displays the measured whole brain volumes and corresponding ﬁts with respect to the SIENAX volume. The bottom row displays the measured gray matter volume ﬁts with
respect to the reference SIENAX volume.
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results. To overcome this in the future, future studies are recommended
to perform blinded analyses. Second, people have debated the accuracy
of BrainWeb to model partial volume eﬀects in a realistic fashion
(Bromiley, 2008), which may explain discrepancies between methods
in the simulated data to a certain extent. However, discrepancies be-
tween methods were also observed in the in vivo data suggesting that
the imperfect PVE model of BrainWeb particularly aﬀected the com-
parison with the reference volume. More realistic simulations (in-
cluding well-characterized artefacts such as noise and inhomogeneity)
and reference datasets should be developed to truly solve this problem.
In addition, longitudinal methods may be investigated using methods
that simulate longitudinal atrophy (Sharma et al., 2013). Third, we
have not corrected P-values for multiple-testing which may have
increased the risk that some observed diﬀerences are actually chance
ﬁndings. However, in this validation paper we have considered it more
appropriate to display uncorrected P-values allowing the reader to
make their own assessment than to apply a formal correction for mul-
tiple comparisons. Another limitation is the hardware upgrade that was
performed between baseline and follow-up. Although this hardware
upgrade was part of regular maintenance, the upgrade interfered sub-
stantially with the longitudinal atrophy measurements and hampered
reliable comparison of the longitudinal methods. The eﬀect was even
worse for the cross-sectional methods, in which the scanner upgrade
had a large inﬂuence on the normalization for head size. This forced us
to be very cautious on making statements on the reliability and accu-
racy of the longitudinal methods and simultaneously stressed the
Table 3
Spearman rank correlations between normalized cross-sectional atrophy measurement results in in vivo MRI data at
baselinea.
A
ll 
su
bj
ec
ts
 (n
 =
 1
18
)
Whole–brain
MSmetrix NBV
FreeSurfer BPF
SIENAX NBV
SPM BPF
MSmetrix NBV
1
FreeSurfer BPF
0.66***
1
SIENAX NBV
0.72***
0.78***
1
SPM BPF
0.87***
0.77***
0.77***
1
Gray matter
MSmetrix NGMV
FreeSurfer GMF
SIENAX NGMV
SPM GMF
MSmetrix NGMV
1
FreeSurfer GMF
0.620***
1
SIENAX NGMV
0.747***
0.793***
1
SPM GMF
0.84***
0.74***
0.78***
1
a Spearman's ρ.
Fig. 4. Scatter plots displaying the agreement of the longitudinal measurements with MSmetrix in the in vivo MRI data.
The top row displays the measured percentage whole brain volume change of FreeSurfer and SIENA with respect the percentage gray matter volume change measured by MSmetrix. The
bottom row displays the measured percentage gray matter volume change measured by FreeSurfer with respect to the percentage gray matter volume change measured by MSmetrix.
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crucial need to always use data from identical scanners and sequences,
also when using MSmetrix. Future research with data that satisﬁes this
requirement is the only way to overcome this limitation. Furthermore,
the size of the longitudinal healthy control group was limited. Although
a comparison between clinical groups was not a purpose of this study,
the heterogeneous group and limited size of this group may explain the
absence of a diﬀerence in atrophy rates between controls and patients
in this study. Finally, the lesion segmentation and ﬁlling approach was
similar for all established atrophy measurement methods, while
MSmetrix used its own implementation. Although it was not reﬂected
by our results and the diﬀerences in lesion volume were small com-
pared to the diﬀerences in lesion volume, we cannot rule out that this
may have caused a slight advantage in terms of agreement between the
established methods, compared to MSmetrix. As a post-hoc analysis, we
therefore also explored the agreement between methods when running
the MSmetrix atrophy measurement algorithm on kNN-TTP/LEAP
preprocessed data, and running the established atrophy measurement
methods on data preprocessed by using MSmetrix. We did not ﬁnd
evident diﬀerences in the results (data not shown).
4.5. Conclusions
In conclusion, our results demonstrated diﬀerences between
MSmetrix, FreeSurfer, FSL and SPM that were large compared to typical
atrophy rates in MS. Especially striking are the proportional errors that
were observed. Cross-sectional MSmetrix behaved much like SPM, both
in terms of mean diﬀerence from the reference (and other methods) as
well as proportional error. Longitudinal MSmetrix was (as the other
longitudinal methods) sensitive to the hardware upgrade that occurred
during the time of the study and behaved most similar to SIENA. Our
results indicate that brain volume measurement and normalization
from T1-weighted images remains an unsolved problem that requires
improvement both on the acquisition and the analysis front.
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Fig. 5. Scatter (left) and Bland-Altman (right) plot displaying the
agreement of MSmetrix and kNN-TTP measuring lesion volumes
in the MS patients at baseline.
Because WM lesion volume is not normally distributed, a log-
converted version of the raw volumes is displayed in the bottom
panels.
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